Comparative characteristic of the effect of anti-inflammatory therapy on the blood and urine levels of growth factors in patients with rheumatoid arthritis

Keywords: chronic kidney disease, transforming growth factor-β1, vascular endothelial growth factor, rheumatoid arthritis

Abstract

The purpose of our work was to compare the effect of aceclofenac and meloxicam on the level of transforming growth factor-β1 (TGFβ1) and vascular endothelial growth factor in the blood and urine in chronic kidney disease (CKD) patients with rheumatoid arthritis (RA).

Methods. RA patients were allocated into three groups: I group included the patients with RA without CKD presence (n = 47), group II – patients with RA with CKD stage 1 (n = 46), group III – patients suffered from RA with CKD stage 2 (n = 45). To form the group of comparison 20 healthy persons of appropriate age category were examined. Complex clinical-laboratory examination of all patients was performed during the period of extensive clinical manifestations (before nonsteroid anti-inflammatory drug (NAIP) administration), in a week and in 2 weeks during carrying out therapy with NAIP. Treatment was also carried out in accordance with the existing principles of therapy RA and of the revealed nephrologic diseases. In a complex of patients’ therapy aceclofenac was included. Influence of aceclofenac was compared with meloxicam. Concentrations of TGFβ1 and vascular endothelial growth factor (VEGF) in the blood and urine were studied using an immunofermental method.

Results. In a week of anti-inflammatory therapy, a significantly decrease in the levels

of the studied factors was found in all patients’ groups. The blood VEGF level was lower by 11.90% in the aceclofenac group compared to the meloxicam group. Urine VEGF and TGFβ1 levels were decreased by 5.53% and 39.40%, respectively, in patients with aceclofenac therapy compared with the meloxicam group. After two weeks of the aceclofenac therapy a significant decrease of TGFβ1 and VEGF in the blood (p<0.05) and urine (p <0.001) of the CKD patients with RA were determined.

Conclusion. The use of aceclofenac as a new generation of NSAIDs for the complex

treatment of patients with RА and comorbid CKD improves the therapy efficiency due to reducing the blood and urine levels of growth factors.

Downloads

Download data is not yet available.

References

Batiushyn MM, Vyistavkyna EA. Klynycheskye proiavlenyia y faktoryi ryska porazhenyia pochek pry revmatoydnom artryte. Fund.yssled. 2012;2:249-52. [In Russian] Available from: http://www.fundamental-research.ru/ru/article/view?id=29487.

Bodnar YA, Klymontov VV, Nadeev AP.  Povyishennaia ekskretsyia transformyruiushcheho faktora rosta-beta – rannyi marker nefropatyy u bolnyikh sakharnyim dyabetom I typa. Sakh.dyabet.2007;2:14-8. [In Russian] Available from: https://cyberleninka.ru/article/v/povyshennaya-ekskretsiya-transformiruyuschego-faktora-rosta-s-mochoy-ranniy-marker-nefropatii-u-bolnyh-saharnym-diabetom-1-tipa).

Dudareva LA, Batiushyn MM. Khronycheskyi tubuloynterstytsyalnyii nefryt, yndutsyrovannyii pryyomom nesteroydnyikh protyvovospalytelnyikh preparatov: epydemyolohycheskye osobennosty y vozmozhnosty rannei dyahnostyky. Nefrolohyia. 2013;5(17): 22-6. [In Russian] Available from: http://www.fesmu.ru/elib/Article.aspx?id=287970.

Zub LO, Roborchuk SV, Dotsiuk LH. Vplyv atseklofenaku na riven pro- ta protyzapalnykh tsytokiniv u khvorykh na revmatoidnyi artryt z naiavnistiu khronichnoi khvoroby nyrok. Ukr.J.Nefr.Dial.2015;3(47):17-21. [In Ukrainian]  doi: 10.31450/ukrjnd.3(47).2015.04.

Zub LO, Kulachek VT. Bukovynskyi derzhavnyi medychnyi universytet, patentovlasnyk. Sposib rannoi diahnostyky urazhen nyrok u khvorykh na revmatoidnyi artryt. Patent Ukrainy №85183. 2013 trav. 27. [In Ukrainian] Available from: http://uapatents.com/5-100230-sposib-ranno-diagnostiki-urazhennya-nirok-u-khvorikh-na-gipotireoz-iz-metabolichnim-sindromom.html.

Naida VT, Zub LO. Porivnialna kharakterystyka pokaznykiv transformuiuchoho faktoru rostu β1 u khvorykh na revmatoidnyi artryt v zalezhnosti vid vydu patolohii nyrok. Klin.ta eksperym.patol. 2011;2(36):72-4. [In Ukrainian].

Rebrov AP, Voloshynova EV, Tiapkyna MA.  Vstrechaemost khronycheskoi bolezny pochek y ee struktura u bolnyikh revmatoydnyim artrytom. Klyn. nefrol.2011;6:32-5. [In Russian]. Available from:  https://lib.medvestnik.ru/articles/Vstrechaemost-hroniches koi-bolezni-pochek-i-ee-struktura-u-bolnyh-revmatoidnym-artritom.html.

Serebrennykova SN, Semynskyi YZh. Rol tsytokynov v vospalytelnom protsesse (soobshchenye 1). Sybyr. med. zh.2008;6: 5-8. [In Russian]. Available from: https://elibrary.ru/item.asp?id=11701608.

Folomeeva OM. K probleme opredelenyia vnesustavnyikh proiavlenyi revmatoydnoho artryta. Nauch.prakt.revmatol. 2008; 2: 74-82. [In Russian]. Available from: http://r-factor.ru/view_art.php?art=49&page=1&ID=0.  

Chebotareva RV, Bobkova YN, Kozlovskaia LV, Varshavskyi VA, Holytsyina EP. Opredelenye ekskretsyy s mochoi monotsytarnoho khemotaksycheskoho proteyna-1 y transformyruiushcheho faktora rosta-β1 u bolnyikh khronycheskym hlomerulonefrytom kak metod otsenky protsessov fybroheneza v pochne. Klyn. Nefr. 2010;3:48-53.   [In Russian]. Available from: https://cyberleninka.ru/article/n/kliniko-laboratornye-markery-obmena-soedinitelnoy-tkani-pri-glomerulonefrite-u-detey.

Hao Q, Wang L, Tang H. Vascular Endothelial Growth Factor Induces Protein Kinase D-dependent Production of Proinflammatory Cytokines in Endothelial Cells. AJP: Cell Physiol.2009;4(296): 821-7. doi: 10.1152/ajpcell.00504.2008.

Yoo SA, Kwok SK, Kim WU. Proinflammatory Role of Vascular Endothelial Growth Factor in the Pathogenesis of Rheumatoid Arthritis: Prospects for Therapeutic Intervention. Mediators of Inflammation. 2008; (2008):129873. doi:  10.1155/2008/129873.

Presta M, Andris G, Leali D, DellEra P, Ronca R. Inflammatory cells and chemokines sustain FGF2-induced angiogenesis. European Cytokine Network. 2009;2(20): 39-50. doi: 10.1684/ecn.2009.0155.

 Sean Eardley K, Cockwell P. Macrophages and progressive tubulointerstitial disease. Kidney Int. 2005;68: 437–55 doi: 10.1111/j.1523-1755.2005.00422.x.

Takamatsu N, Tominaga T. Risk factors for chronic kidney disease in Japan: a communitybased study. BMC Nephrol. 2009;10: 34–44. doi:  10.1038/kisup.2013.79. 

Published
2018-12-26
How to Cite
Zub, L., & Roborchuk, S. (2018). Comparative characteristic of the effect of anti-inflammatory therapy on the blood and urine levels of growth factors in patients with rheumatoid arthritis. Ukrainian Journal of Nephrology and Dialysis, (4(60), 28-34. https://doi.org/10.31450/ukrjnd.4(60).2018.04